SomaLogic, Inc., a company involved in proteomics technology, is extending its collaborative agreement with Novo Nordisk. As part of the agreement, which now extends into the end of 2025, Novo Nordisk will expand its use of the SomaScan proteomics platform in drug research and development. Novo Nordisk will also use SomaLogic’s SomaSignal tests for investigations into cardiometabolic and other diseases. The extension builds upon an agreement between the two companies, which was announced in 2021.

Novo Nordisk previously partnered with SomaLogic to provide proteins of interest that expanded the SomaScan platform’s previous offering to its current offering of more than 7,000 proteins. SomaLogic’s proprietary protein detection and analysis technology measures how proteins function and interact, supporting researchers in drug research and development, and biomarker identification efforts.

“SomaLogic has been very pleased with our partnership with Novo Nordisk which spans more than a decade,” said SomaLogic CEO Adam Taich. “We are proud that our SomaScan platform is being used in their research and development of new potential treatments for serious chronic diseases.”